American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 635-637 , November 2008

Update on Antiviral Treatment of Adenoviral Ocular Infections

  • Eric G. Romanowski
    • ,
  • Y. Jerold Gordon

      Affiliations

    • Corresponding Author InformationInquiries to Y. Jerold Gordon, The Eye & Ear Institute, Room 1023, University of Pittsburgh, 203 Lothrop Street, Pittsburgh, PA 15213

,Accepted 15 July 2008.

References 

  1. Murrah WF. Epidemic keratoconjunctivitis. Ann Ophthalmol. 1988;20:36–38
  2. Uchio E, Fuchigami A, Kadonosono K, et al. Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2007;245:1319–1325
  3. Gordon JS, Aoki K, Kinchington PR. Adenovirus keratoconjunctivitis. In:  Pepose JS,  Holland GN,  Wilhelmus KR editor. Ocular Infection & Immunity. St Louis, Missouri: Mosby; 1996;p. 877–894
  4. American Academy of Ophthalmology. Preferred Practice Pattern, Adenoviral Conjunctivitis. http://one.aao.org/CE/PracticeGuidelines/PPPAccessed: May 20, 2008
  5. Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42:1812–1815
  6. Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology. 2002;109:845–850
  7. Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophthalmol Vis Sci. 2006;47:2021–2026
  8. Nagl M, Gottardi W. Enhancement of the bactericidal efficacy of N-chlorotaurine by inflammation samples and selected N-H compounds. Hyg Med. 1996;21:597–605
  9. Nagl M, Miller B, Daxecker F, Ulmer H, Gottardi W. Tolerance of N-chlorotaurine, an endogenous antimicrobial agent, in the rabbit and human eye—a phase I clinical study. J Ocular Pharmacol Ther. 1998;14:283–290
  10. Nagl M, Teuchner B, Pöttinger E, Ulmer H, Gottardi W. Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis—a phase II pilot study. Ophthalmologica. 2000;214:111–114
  11. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis—a double-blind, randomized, phase-2 clinical trial. J Ocular Pharmacol Ther. 2005;21:157–165
  12. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmology. 2006;6:22
  13. Asbell PA, Epstein SP, Wallace JA, Epstein D, Stewart CC, Burger RM. Efficacy of cobalt chelates in the rabbit eye model for epithelial herpetic keratitis. Cornea. 1998;17:550–557
  14. Hartley C, Hartley M, Pardoe I, Knight A. Ionic contra-viral therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol. 2006;151:2495–2501
  15. Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A. Efficacy of topical immunoglobulins (IG) against experimental adenoviral ocular infection. Invest Ophthalmol Vis Sci. 2007;48:4171–4176
  16. Van der Vliet PC, Kwant MM. Role of DNA polymerase γ in adenovirus DNA replication (Mechanism of inhibition by 2,′2′-dideoxynucleoside 5′-triphosphates). Biochemistry. 1981;20:2628–2632
  17. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol. 1991;41:1821–1829
  18. Marquez VE, Lim MI, Treanor SP, et al. Cyclopentenylcytosine (A carbocyclic nucleoside with antitumor and antiviral properties). J Med Chem. 1988;31:1687–1694

PII: S0002-9394(08)00582-5

doi: 10.1016/j.ajo.2008.07.030

American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 635-637 , November 2008

Article Tools